PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- AbbVie’s 8-Week Hep C Therapy Filed in Japan
February 15, 2017
- Otsuka Aims for Abilify Maintena’s 30% Share in LAI Antipsychotic Market
February 15, 2017
- Otsuka’s 2016 Earnings Falter as Abilify Sales Dive 70%
February 15, 2017
- Bisphosphonates Grab Top Share, PTH Preparations Expand in FY2015 Osteoporosis Market: Report
February 14, 2017
- Test Urine Copper in Pregnant Women Taking Nobelzin: Nobelpharma
February 14, 2017
- Maruho to Hand Over Joint Disorder Med to Ayumi
February 14, 2017
- Otsuka Aims to Resubmit NDA for Sensor-Embedded Abilify in US by Mid-Year
February 14, 2017
- Sawai Gets FDA Nod for Livalo Generic
February 13, 2017
- Daiichi Sankyo Shutters Research Unit Asubio amid R&D Rejig
February 13, 2017
- Novartis Seeks Pediatric CML Indication for Tasigna
February 13, 2017
- Bayer Yakuhin Ramping Up Digital Transformation: New President
February 10, 2017
- Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan
February 10, 2017
- Sandoz Looks to Double Japan Sales by 2022
February 9, 2017
- Ethical Drug Sales Down 8.2% in December: Crecon
February 8, 2017
- OrphanPacific to Distribute Diazoxide from April
February 7, 2017
- Akihisa Nabeshima to Become Teijin Pharma President
February 7, 2017
- FDA Snubs Daiichi Sankyo’s Nausea Med
February 7, 2017
- ASKA to Absorb Former Actavis JV
February 7, 2017
- Sanofi, Yakult Honsha Link Arms on Zaltrap
February 7, 2017
- Ex-Lilly Exec Tsunaba Tapped as Novartis Japan Chief
February 7, 2017
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…